Company / Net Income
Exelixis Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$782.6M
FY2025
5-year range
$111.8M / $782.6M
FY2021-FY2025
Trend
+50.1%
vs FY2024
Sector context
#18 of 216
Health Care
What the data says
Among 216 Health Care companies, Exelixis is in the top 8% for net income. Net Income has increased for 3 consecutive years, from $112M in FY2022 to $783M in FY2025.
Based on SEC 10-K filings.
$783M in FY2025 with a 5-year CAGR of +47.6%. Top quartile in the Health Care sector.
Improved from $208M to $783M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +91.3%
- 5-Year CAGR
- +47.6%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 216This company $782.6M Sector average $454.1M
▼
+72.3% above sector average
Key checks
Key Insights
- Exelixis's net income has grown for 3 consecutive years.
- 5-year CAGR of +47.6%, indicating consistent growth.
- In FY2025, net income increased 50.1% year-over-year.
- Ranks #18 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.33 (safe zone, above 2.9 threshold)
- Strong profit margin: 29.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 31.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $782.6M | +50.1% |
| FY2024 | $521.3M | +150.9% |
| FY2023 | $207.8M | +85.9% |
| FY2022 | $111.8M | -65.2% |
| FY2021 | $321.0M | +187.2% |
| FY2020 | $111.8M | -65.2% |
| FY2019 | $321.0M | +557.1% |
| FY2018 | -$70.2M | -145.5% |
| FY2017 | $154.2M | +319.6% |
| FY2016 | -$70.2M | +56.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026